Pfizer LianBio Collaborate To Bring Novel Therapeutics In Greater China

US-based Pfizer, Inc. and Shanghai-based LianBio have recently announced that they have entered into a collaboration aimed at developing and commercializing transformative pharmaceutical products in Greater China. LianBio, founded by Perceptive Advisors, forged a collaboration with Pfizer to pursue an innovative business development opportunity. Both companies will be dedicated to advancing best-in-class therapies for patients, leveraging both LianBio’s and Pfizer’s clinical development, regulatory and commercial expertise. “We are honored to partner with Pfizer, a significant pioneer in the industry, to build upon their extensive commercial engine in Greater China, as well as tap into their relationships with leading physicians specializing in a broad range of therapeutic areas,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman of LianBio. “LianBio’s well-established sourcing capabilities, derived from Perceptive Advisors and other world class investors, will enable our partnership to bring precision-based medicines to patients in Greater China. This deal also provides LianBio additional non-dilutive funding to build out and advance our robust and diverse pipeline of innovative therapies targeting a variety of diseases.” In addition to Pfizer’s participation in LianBio’s recent crossover financing, under the terms of the collaboration, Pfizer will contribute up to $70M of non-dilutive capital toward in-licensing and co-development. At LianBio’s discretion, products will be presented to Pfizer for joint development. Pfizer will have a right of first negotiation to obtain commercial rights to jointly developed assets and each will carry separate financial considerations. During the collaboration, Pfizer may provide in-kind support for marketing, development and regulatory activities.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!